Stock Events

Embecta 

$13.6
30
+$0.4+3.03% Wednesday 20:00

Statistics

Day High
13.68
Day Low
13.05
52W High
22.39
52W Low
9.7
Volume
347,814
Avg. Volume
439,875
Mkt Cap
784.31M
P/E Ratio
11.24
Dividend Yield
4.41%
Dividend
0.6

Upcoming

Dividends

4.41%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

9MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
0
0.39
0.79
1.18
Expected EPS
0.4
Actual EPS
0.67

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EMBC. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Medtronic
MDT
Mkt Cap99.95B
Medtronic is a major player in the medical devices sector, directly competing with Embecta in the diabetes management space, including insulin pumps and glucose monitoring systems.
Abbott Laboratories
ABT
Mkt Cap181.3B
Abbott Laboratories offers a wide range of medical devices, diagnostics, and nutritional products, competing with Embecta in areas such as glucose monitoring.
Dexcom
DXCM
Mkt Cap45.36B
DexCom specializes in continuous glucose monitoring (CGM) systems, a direct competitor to Embecta's diabetes care products.
Tandem Diabetes Care
TNDM
Mkt Cap2.98B
Tandem Diabetes Care is a direct competitor in the insulin pump market, offering advanced diabetes management systems.
Insulet
PODD
Mkt Cap14.15B
Insulet Corporation specializes in tubeless insulin pump technology, competing in the insulin delivery market alongside Embecta.
Novo Nordisk
NVO
Mkt Cap481.67B
Novo Nordisk is a global healthcare company with a strong focus on diabetes care, including insulin and devices, competing with Embecta's offerings.
Sanofi
SNY
Mkt Cap130B
Sanofi is involved in diabetes care through its insulin and glucose monitoring products, making it a competitor to Embecta.
Bristol-Myers Squibb
BMY
Mkt Cap82.02B
Bristol Myers Squibb, through its acquisition of MyoKardia, has expanded into various healthcare sectors, potentially competing with Embecta in the broader medical devices and healthcare market.
Johnson & Johnson
JNJ
Mkt Cap360.71B
Johnson & Johnson, through its medical devices segment, competes in the healthcare market, including areas that overlap with Embecta's diabetes care products.
Boston Scientific
BSX
Mkt Cap114.22B
Boston Scientific Corporation operates in the medical devices sector, competing in various areas that could intersect with Embecta's market, including diabetes care solutions.

Analyst Ratings

12$Average Price Target
The highest estimate is $12.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
0%
Sell
100%

About

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
Show more...
CEO
Employees
2200
Country
US
ISIN
US29082K1051
WKN
000A3DGNE

Listings